<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315925</url>
  </required_header>
  <id_info>
    <org_study_id>751/2009</org_study_id>
    <nct_id>NCT01315925</nct_id>
  </id_info>
  <brief_title>Pre-hospital Risk Factors for Invasive Fungal Infection</brief_title>
  <acronym>SEIFEM 2010</acronym>
  <official_title>SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      SEIFEM 2010 study is a prospective, multicenter registry designed to identify and analyze
      risk factors for developing an invasive fungal infection in patients with newly diagnosed
      Acute Myeloid Leukemia, with particular interest on pre-hospital risk factors (i.e. those
      related to normal activities of daily life, such as occupation, location and type of
      residence, consume of tobacco, alcohol and others).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SEIFEM 2010:

      EPIDEMIOLOGICAL SURVEY ON POSSIBLE PRE-HOSPITAL RISK FACTORS FOR DEVELOPING INVASIVE FUNGAL
      INFECTIONS IN PATIENTS AFFECTED BY ACUTE MYELOID LEUKEMIA

      Background:

      In two different multicenter surveys conducted in Italy from 1988-1997 and 1999-2003,
      (Invasive Fungal Infections) IFIs were found to be a frequent cause of morbidity and
      mortality in patients treated with conventional chemotherapies, particularly in those
      suffering from acute myeloid leukemia (AML).

      In general, the major factors that have been recognized as influencing the likelihood of
      invasive fungal infection are the patient's immune status, the degree of any organ damage
      (e.g., mucositis), and overall microbial exposure (i.e., colonization, environment, and prior
      infection). Since the 1990s, different risk-stratification strategies have been evaluated in
      order to identify those patients who may benefit from intensive prophylactic and diagnostic
      measures. However, despite having similar risk profiles, only a subset of AML patients will
      develop an IFI. One of the most exciting recent advances in the understanding of the
      epidemiology of IFIs is the recognition of the complexity of the host and the identification
      of new host-related risk factors.

      Aim of this study is to identify and analyze risk factors for developing an invasive fungal
      infection in patients with newly diagnosed Acute Myeloid Leukemia, with particular interest
      on pre-hospital risk factors.

      Aims and objective:

        -  To identify high risk subjects that can take advantage of an antifungal prophylaxis or
           an early antifungal treatment (preemptive treatment).

        -  To identify possible fungal infections sources for the period preceding the diagnosis of
           leukemia, in particular those related to normal activities of daily life (e.g.
           occupation, location and type of residence, consume of tobacco, alcohol or illicit drugs
           and others).

        -  To analyze hospital-related sources of fungal infection, from well known predisposing
           factors (i.e. duration and severity of neutropenia) to other like central venous
           catheter, urinary catheter, comorbidities, etc.

        -  To analyze the impact of both the prophylactic regimen adopted and the antifungal
           treatment.

      Design:

        -  Prospective, multicenter, observational and clinical-epidemiological study.

        -  The study is expected to enroll at least 500 patients with newly diagnosed acute myeloid
           leukemia, those eligible for treatment and those not eligible, within 2 years or until
           the achievement of a statistically evaluable number of cases.

        -  SEIFEM 2010 is a noninterventional registry and therefore there will not be any any
           change physicians' diagnostic and therapeutic choices, that remain related to local
           guidelines.

        -  Every patient who accept to take part to the study, will be asked to read and sign an
           informed consent.

        -  An apposite form, with a detailed epidemiological section, should be compiled by
           clinicians for each enrolled patient.

        -  A complete information page on the study is supplied to each patient enrolled.

      Data collection:

      In the questionnaire, possible risk factors for invasive fungal infections, prior to the
      onset of acute leukemia, are evaluated. The module consists of several sections:

        -  Personal information (age, sex, observation time of the case, AML subtype, performance
           status at admission), patient data will be anonymous.

        -  Comorbidities (diabetes, chronic renal failure, COPD, chronic liver disease, previous
           TBC)

        -  A section compiled by the patient about possible risk factors related to the daily
           living habits (location and type of residence, profession, hobbies, pets, personal
           hygiene, ambiental exposures, consume of tobacco, alcohol or illicit drugs and others)

        -  A second part of the form will be compiled at the time of evaluation after induction
           chemotherapy (between 30 and 40 days after chemotherapy) or, for those not suitable for
           conventional treatment, 30-40 days after diagnosis.

      At the time of a diagnosis of fungal infection data on the type of infection, treatment and
      course of infection will be evaluated.

      Eligibility:

      Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and
      not eligible for intensive chemotherapy. Since this is a noninterventional study, therapeutic
      strategies remains related to local guidelines. Will be treated as cases all patients with
      acute leukemia in first induction developing an Invasive Fungal Infection according to
      international EORTC criteria for possible/probable/proven infections. Patients who do not
      develop the infection will be used as a control group.

      Participating centers:

      Forty-three Italian divisions of Hematology will take part to the study, distributed among
      universities and highly specialized hospitals located throughout the country.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Invasive fungal infections</measure>
    <time_frame>30th day after the end of first line chemotherapy</time_frame>
    <description>To identify possible fungal infections sources for the period preceding the diagnosis of leukemia, in particular those related to normal activities of daily life (e.g. occupation, location and type of residence, consume of tobacco, alcohol or illicit drugs and others).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Aspergillosis</condition>
  <condition>Candidiasis</condition>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>Newly disgnosed AML</arm_group_label>
    <description>Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and
        not eligible for intensive chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all newly diagnosed AML who accept to take part to the registry and sign an informed
             consent

        Exclusion Criteria:

          -  relapsing/refractory AML

          -  patients who do not sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Ancona</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Offidani, MD</last_name>
      <email>m.offidani@ao-umbertoprimo.marche.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Offidani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bary</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Delia, MD</last_name>
      <email>mario.delia74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Delia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Vianelli</last_name>
      <email>nicola.vianelli@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Vianelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Firenze</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Fanci, MD</last_name>
      <email>r.fanci@dac.unifi.it</email>
    </contact>
    <investigator>
      <last_name>Rosa Fanci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tricase Hospital</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niguarda Hospital</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Nosari, MD</last_name>
      <email>annamaria.nosari@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Annamaria Nosari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livio Pagano, MD</last_name>
      <phone>+390630154180</phone>
      <email>lpagano@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Livio Pagano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morena Caira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Mancinelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IFO</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.Camillo Hospital</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Garzia</last_name>
      <email>mariagraziagarzia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.Giovanni Hospital</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Chierichini</last_name>
      <email>annachierichini@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tor Vergata</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Venditti</last_name>
      <email>adriano.venditti@uniroma2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Molinette Hospital</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Busca</last_name>
      <email>abusca@molinette.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Cattaneo, MD</last_name>
      <email>chiara.cattaneo@libero.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Cattaneo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Rossi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cagliari</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Vacca</last_name>
      <email>vaccaadriana@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasbarrino</last_name>
      <email>gasbacri@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Storti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cuneo Hospital</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istotuto Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Caselli</last_name>
      <email>d.caselli@meyer.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaslini Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elio Castagnola</last_name>
      <email>eliocastagnola@ospedale-gaslini.ge.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Spezia Hospital</name>
      <address>
        <city>La Spezia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annunziata Manna</last_name>
      <email>annunziata.manna@asl5.liguria.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lecce Hospital</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De Paolis</last_name>
      <email>depaolis.ematolecce@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lecce Pediatric Hospital</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Modena e Reggio</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Luppi</last_name>
      <email>mluppi@unimore.it</email>
    </contact>
    <investigator>
      <last_name>Mario Luppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monza Hospital</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Verga</last_name>
      <email>luisa.verga@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Federico II&quot; University</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Picardi, MD</last_name>
      <email>picardi@ceinge.unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardarelli Hospital</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pausilion Hospital</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Enza Mitra</last_name>
      <email>memitra@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria Enza Mitra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Caramatti</last_name>
      <email>cecilia.caramatti@unipr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.Matteo Hospital, Department of Hematology</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Castagnola</last_name>
      <email>castagnola@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Castagnola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.Matteo Hospital, Department of Medicine</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosangela Invernizzi</last_name>
      <email>r.invernizzi@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Perugia, Pediatric Hematology</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Aversa</last_name>
      <email>aversa@unipg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Aversa</last_name>
      <email>aversa@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Franco Aversa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pescara Hospital</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prassede Salutari</last_name>
      <email>prassede.salutari@email.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reggio Calabria Hospital</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Martino</last_name>
      <email>brunmartin@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reggio Emilia Hospital</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bonini</last_name>
      <email>Alessandro.Bonini@asmn.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Padre Pio&quot; Hospital</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorella Melillo</last_name>
      <email>l.melillo@operapadrepio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regina Margherita Hospital</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.Anna Hospital</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mareva Giacchino</last_name>
      <email>mareva.giacchino@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Candoni</last_name>
      <email>candoni.anna@aoud.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianpaolo Nadali</last_name>
      <email>gianpaolo.nadali@univr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verona Hospital</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro</last_name>
      <email>simone.cesaro@azosp.vr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Caira M, Mancinelli M, Leone G, Pagano L. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med Mycol. 2011 Apr;49 Suppl 1:S13-6. doi: 10.3109/13693786.2010.509138. Epub 2010 Aug 26.</citation>
    <PMID>20795761</PMID>
  </reference>
  <reference>
    <citation>Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005 Apr;19(4):545-50.</citation>
    <PMID>15729382</PMID>
  </reference>
  <reference>
    <citation>Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010 Apr;95(4):644-50. doi: 10.3324/haematol.2009.012054. Epub 2009 Oct 22.</citation>
    <PMID>19850903</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Livio Pagano, MD</name_title>
    <organization>Catholic University of the Sacred Heart</organization>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>invasive fungal infection</keyword>
  <keyword>Aspergillosis</keyword>
  <keyword>candidiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

